- Supported exchanges /
- F /
- 9UA.F
NERVGEN PHARMA CORP. (9UA F) stock market data APIs
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
NERVGEN PHARMA CORP. Financial Data Overview
| 1.45 | |
| 1.44 | |
| - | |
| 1.45 | |
| 1.44 | |
| 1.06-2.74 | |
| 110 M | |
| 70 180 K | |
| 0 | |
| 1.329 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
NERVGEN PHARMA CORP. Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -19 244 188
- Earnings Per Share -0.25
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get NERVGEN PHARMA CORP. Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get NERVGEN PHARMA CORP. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
